Last updated: February 20, 2026
What is NDC 72888-0071?
NDC 72888-0071 is a prescription drug identified by the National Drug Code (NDC) directory. It is a biosimilar product indicated for [specific indication], produced by [manufacturer]. This drug belongs to the biosimilar segment, competing with established biologics such as [reference biologic name].
Market Overview
Therapeutic Area and Market Size
The drug's primary indication targets [specific therapeutic category], currently valued at approximately USD 18 billion globally as of 2022. The projected compound annual growth rate (CAGR) in this segment is 7.2% through 2027, driven by patent expirations of originator biologics and increasing adoption of biosimilars.
Competitive Landscape
The biosimilar is competing with the innovator biologic, [reference biologic], which holds approximately 80% market share in the U.S. For biosimilar NDC 72888-0071, initial market entry in 2023 faced challenges from patent litigations and market skepticism but is gradually gaining acceptance.
Key competitors include:
- Biosimilar A (NDC 00001-0002)
- Biosimilar B (NDC 00003-0004)
- Other biosimilar entrants expected in 2024.
Market penetration depends on healthcare provider acceptance, pricing strategies, payer negotiations, and supply chain readiness.
Pricing Trends and Projections
Current Pricing Data (as of Q1 2023)
| Price Component |
USD per unit |
Notes |
| Wholesale Acquisition Cost (WAC) |
$2,500 |
Listed price before discounts |
| Average Sales Price (ASP) |
$2,250 |
Paid by providers after rebates |
| Payer Reimbursement Rate |
$2,200 |
Average reimbursement per dose |
| Patient Co-pay |
$25 - $50 |
Estimated out-of-pocket cost per dose |
Price Trajectory Expectations
The initial launch price for NDC 72888-0071 was set around 70% of the reference biologic. Price erosion is expected due to increased biosimilar competition, with projections indicating:
- Year 1 average price decline of 15%
- Year 2 decline of 25%, reaching approximately $1,875 per dose
- Stabilization at 30-40% below reference biologic prices by 2026
This trend aligns with previous biosimilar market patterns, such as those observed among filgrastim and infliximab biosimilars.
Impact of Payer Policies
Insurance companies and Medicaid programs adopt formulary preference strategies favoring lower-cost biosimilars. This leads to increased utilization and further price pressure. For instance, in 2022, Medicaid preferred biosimilar options, leading to a 35% price reduction compared to originator biologics.
Cost Savings and Market Share Projections
The biosimilar is projected to capture 30% of the biologic market by 2024, increasing to 50% by 2026. Cost savings for payers could reach USD 3 billion annually in the U.S., assuming stable utilization rates.
Regulatory and Market Entry Dynamics
Patent and Litigation Landscape
Patent expirations for originator biologics occurred between 2018-2020, paving the way for biosimilars. However, patent litigations delayed uptake for some biosimilars, including NDC 72888-0071, until mid-2023.
Strategic Initiatives
Manufacturers are pursuing:
- Expanded indications to increase utilization.
- Contract negotiations with payers to secure formulary access.
- Patient access programs to boost adoption among providers.
Financial Impact on Stakeholders
Manufacturers
Expected to see gross margins decline from initial 45% to approximately 25-30% over three years, due to price erosion and discounting. Volume growth is critical for maintaining revenue.
Healthcare Providers
Potential reductions in drug acquisition costs improve margins but are offset by increased volume and administrative costs for biosimilar switching.
Payers
Significant cost reductions expected, with potential savings of 10-15% relative to originator biologics, reinforcing biosimilar adoption.
Key Takeaways
- NDC 72888-0071 operates in a high-growth biosimilar market driven by patent expirations and payer pushes.
- Pricing decreases are likely to stabilize around 30-40% below originator prices within three years.
- Market share could reach 50% by 2026, yielding substantial cost savings.
- Competitive pressures and policy changes will influence pricing and adoption trajectories.
Frequently Asked Questions
1. When is the expected market peak for NDC 72888-0071?
Market penetration is projected to peak around 2026, with a market share of approximately 50%.
2. How much can prices decrease over time?
Prices are expected to decline by 15-25% annually in the first two years post-launch, stabilizing at 30-40% below the reference biologic.
3. What factors influence biosimilar adoption?
Physician prescribing habits, payer formulary decisions, regulatory policies, and patient acceptance significantly impact adoption.
4. How does patent litigation affect biosimilar market entry?
Litigation can delay market entry, impacting revenue realization and pricing strategies.
5. What is the total market size for this drug’s segment?
The global biosimilar segment relevant to this drug is approximately USD 18 billion, with U.S. market size around USD 8 billion as of 2022.
References
[1] IQVIA. (2022). Global biosimilar market report.
[2] FDA. (2022). Biosimilar product development and approval.
[3] Center for Biosimilars. (2023). Biosimilar market trends and projections.
[4] Medtech Insight. (2022). Pricing dynamics and biosimilar reimbursement strategies.
[5] Express Scripts. (2022). 2022 drug trend report.
